证券日报网讯1月16日，智飞生物（300122）在互动平台回答投资者提问时表示，公司以"防未病治已 病，守护人类健康"为使命，依托智飞绿竹、智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心 的战略布局，实现"预防&治疗"协同发展。宸安生物聚焦糖尿病、肥胖等代谢类疾病领域，围绕GLP-1 类似物、胰岛素类似物等领域进行在研管线布局，详情请关注公司的信息披露。 ...

Core Viewpoint - Zhifei Biological is acquiring a controlling stake in Chongqing Chanan Biopharmaceutical Co., Ltd. through a capital increase, marking its first capital operation to gain control over another company since its listing in 2025 [1][2]. Group 1: Acquisition Details - Zhifei Biological plans to invest nearly 600 million yuan to gain control of Chanan Biopharmaceutical, which focuses on therapeutic biopharmaceuticals [2]. - Chanan Biopharmaceutical has invested nearly 700 million yuan in its research pipeline over the past decade, with key products nearing commercialization [2][4]. - The agreement emphasizes supporting Chanan's therapeutic biopharmaceutical business for high-quality development [2][3]. Group 2: Product Pipeline and Market Potential - Chanan Biopharmaceutical's core products, including semaglutide injection for diabetes and weight loss, are in advanced clinical stages [3][4]. - The global market for GLP-1 drugs is projected to exceed 100 billion USD by 2030, with semaglutide sales in China expected to grow from 2.5 billion RMB in 2022 to 43.9 billion RMB by 2032, reflecting a compound annual growth rate of 33.0% [4][5]. - The company has a robust pipeline with over ten projects in development, including semaglutide and insulin analogs, positioning it among the industry leaders [5][6]. Group 3: Strategic Implications - This acquisition aligns with Zhifei Biological's strategy of integrating prevention and treatment, enhancing its market competitiveness and risk resilience [7][8]. - The transaction is seen as a significant step in Zhifei's long-term strategy to expand into therapeutic drug development, thereby diversifying its business beyond vaccines [8][9]. - The collaboration is expected to leverage Zhifei's extensive sales network to enhance the commercialization prospects of Chanan's products [8].